Extent of non-adherence and non-persistence in asthma patients: analysis of a large claims data set

Maywald, Ulf; Timmermann, Hartmut; Unmüßig, Victoria; Müller, Sabrina; Wilke, Thomas; Welte, R

doi:10.1080/02770903.2021.1871738

Cited by 4 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-persistence was defined as LLT discontinuation with a ≥ 90-day prescription gap between the end of the initial prescription and the dispensation of a new one. A sensitivity analysis for persistence was conducted using a prescription gap of 180 days, in line with previously published studies [ 13 , 14 ]. In such cases, treatment duration was analyzed for each of the LLT regimens.…”

Section: Methodsmentioning

confidence: 99%

Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany

Koenig,

Lorenz,

Beier

et al. 2023

Clin Res Cardiol

View full text Add to dashboard Cite

Background Cardiovascular disease is the leading cause of mortality in Germany. Cardiovascular risk can be mitigated with long-term lipid-lowering therapies (LLTs) that reduce levels of low-density lipoprotein cholesterol. Although effective, risk mitigation is hindered by poor persistence and adherence. Objective To investigate real-world persistence and adherence to LLTs through 36 months post-initiation. Methods This retrospective cohort study included patients with dyslipidemia who were newly prescribed LLTs between July and December 2017, using anonymized prescription data from the Insight Health™ Patient Insight Tool, and followed up until March 2021. Persistence and adherence to the therapies were stratified by age and sex. The proportion of days covered (PDC) was used to measure adherence. Results Patients with dyslipidemia and newly prescribed statins (n = 865,732), ezetimibe (n = 34,490), or anti-proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (anti-PCSK9 mAbs; n = 1940) were included. Persistence to LLTs declined gradually across all treatment subgroups and was lower in women than men. Adherence, calculated as the mean PDC at the end of the analysis period (July 2017‒March 2021) was 0.84, 0.92, and 0.93 for statins, ezetimibe, and anti-PCSK9 mAbs, respectively. Among patients who discontinued treatment, mean treatment duration was 265, 255, and 387 days for statins, ezetimibe, and anti-PCSK9 mAbs, respectively. Only ~ 10% of patients persisted between 201 and 300 days. By Day 300, 71% of patients on statins had discontinued treatment. At 36 months, overall persistence rates were lowest with statins (20.6%), followed by ezetimibe (22.3%) and anti-PCSK9 mAbs (50.9%). Conclusions High non-persistence rates were observed across all LLT regimens analyzed, with the lowest persistence rates observed with statins. Graphical Abstract

show abstract

Section: Methodsmentioning

confidence: 99%

Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany

Koenig,

Lorenz,

Beier

et al. 2023

Clin Res Cardiol

View full text Add to dashboard Cite

show abstract

“…When talking about a patient's lack of adherence, we have to consider both intentional and unintentional issues. [17][18][19] The intentional non-adherence is the consequence of an active and rational decision following the patient's evaluation of the advantages and disadvantages of the prescribed treatment. Of course, the decisionmaking process is highly influenced by the overall information at each individual's disposal.…”

Section: Mild-to-moderate Asthma -Reasons For Poor Controlmentioning

confidence: 99%

Uncontrolled Asthma: Unmet Needs in the Management of Patients

Caminati

Vaia

Furci

et al. 2021

JAA

View full text Add to dashboard Cite

The recent scientific research has provided clinicians with the tools for substantially upgrading the standard of care in the field of bronchial asthma. Nevertheless, satisfactory asthma control still remains an unmet need worldwide. Identifying the major determinants of poor control in different asthma severity levels represents the first step towards the improvement of the overall patients’ management. The present review aims to provide an overview of the main unmet needs in asthma control and of the potential tools for overcoming the issue. Implementing a personalized medicine approach is essential, not only in terms of pharmacological treatments, biologic drugs or sophisticated biomarkers. In fact, exploring the complex profile of each patient, from his inflammation phenotype to his preferences and expectations, may help in filling the gap between the big potential of currently available treatments and the overall unsatisfactory asthma control. Telemedicine and e-health technologies may provide a strategy to both optimize disease assessment on a regular basis and enhance patients’ empowerment in managing their asthma. Increasing patients’ awareness as well as the physicians’ knowledge about asthma phenotypes and treatment options besides corticosteroid probably represent the key and more difficult goals of all the players involved in asthma management at every level.

show abstract

A Call for the United States to Accelerate the Implementation of Reliever Combination Inhaled Corticosteroid–Formoterol Inhalers in Asthma

Krings

Gerald

Blake

et al. 2023

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Extent of non-adherence and non-persistence in asthma patients: analysis of a large claims data set

Cited by 4 publications

References 35 publications

Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany

Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany

Uncontrolled Asthma: Unmet Needs in the Management of Patients

A Call for the United States to Accelerate the Implementation of Reliever Combination Inhaled Corticosteroid–Formoterol Inhalers in Asthma

Contact Info

Product

Resources

About